iBio Launches Public Offering to Advance Immuno-Oncology Pipeline

iBio, a preclinical stage biotechnology company, has launched a public offering to advance its pipeline of precision antibodies developed using artificial intelligence. The company's StableHu technology enables the prediction of new antibody treatments for hard-to-target cancers and other diseases. Its pipeline includes IBIO-101, an anti-CD25 monoclonal antibody that targets immunosuppressive Treg cells to inhibit solid tumor growth.

iBio, Inc. (Nasdaq: IBIO), a preclinical stage biotechnology company specializing in the development of precision antibodies, has launched a public offering to fund its pipeline of innovative biopharmaceuticals [1]. The company leverages artificial intelligence (AI) and computational biology to discover new antibody treatments for hard-to-target cancers and other diseases [1].

iBio's StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody [1]. This technology enables the company to develop biopharmaceuticals using 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases [1].

The company's pipeline includes several immuno-oncology targets, such as IBIO-101, an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors [1]. Other targets in the pipeline include TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5.

The public offering, which commenced on August 18, 2025, involves the sale of pre-funded warrants and Series G and H warrants, with proceeds intended to advance preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and to continue progress on other preclinical pipeline assets and working capital requirements [2]. Leerink Partners is acting as the lead bookrunning manager for the offering, with LifeSci Capital and Oppenheimer & Co. as additional bookrunning managers [2].

iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine by combining proprietary 3D modeling with innovative drug discovery platforms [2]. The company aims to address significant unmet medical needs in cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases.

References:
[1] https://www.marketscreener.com/news/ibio-launches-public-offering-to-advance-preclinical-pipeline-ce7c51dcdd88f122
[2] https://www.morningstar.com/news/globe-newswire/9514338/ibio-announces-proposed-public-offering